Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Jun;28(6):273-282.
doi: 10.14744/AnatolJCardiol.2024.4218.

Adherence to Current Dyslipidemia Guideline in Patients Utilizing Statins According to Risk Groups and Gender Differences: The AIZANOI Study

Taner Şen  1 , Lale Dinç Asarcıklı  2 , Saadet Güven  3 , Umut Kocabaş  4 , Mehmet Özgeyik  5 , Mevlüt Demir  1 , Tülay Oskay  6 , Halil İbrahim Durmuş  7 , Belma Kalaycı  8 , Muhammet Cihat Çelik  9 , Fatih Kahraman  7 , Ökkeş Utku  7 , Mehmet Ali Astarcıoğlu  1 , Sabiye Yılmaz  1 , Abdullah Tunçez  10
Affiliations
Observational Study

Adherence to Current Dyslipidemia Guideline in Patients Utilizing Statins According to Risk Groups and Gender Differences: The AIZANOI Study

Taner Şen et al. Anatol J Cardiol. 2024 Jun.

Abstract

Background: The aim of this study was to assess the adherence to the current European Society of Cardiology dyslipidemia guidelines, the ratio of reaching target values according to risk groups, and the reasons for not reaching LDL-cholesterol (LDL-C) goals in patients on already statin therapy in a cardiology outpatient population.

Methods: The AIZANOI study is a multi-center, cross-sectional observational study including conducted in 9 cardiology centers between August 1, 2021, and November 1, 2021.

Results: A total of 1225 patients (mean age 62 ± 11 years, 366 female) who were already on statin therapy for at least 3 months were included. More than half (58.2%) of the patients were using high-intensity statin regimens. Only 26.2% of patients had target LDL-C level according to their risk score. Despite 58.4% of very high-risk patients and 44.4% of high-risk patients have been using a high-intensity statin regimen, only 24.5% of very-high-risk patients and only 34.9% of high-risk patients have reached guideline-recommended LDL-C levels. Most prevalent reason for not using target dose statin was physician preference (physician inertia) (40.3%).

Conclusion: The AIZANOI study showed that we achieved a target LDL-C level in only 26.2% of patients using statin therapy. Although 58.4% of patients with a very high SCORE risk and 44.4% of patients with a high SCORE risk were using a target dose statin regimen, we were only able to achieve guideline-recommended LDL-C levels in 24.5% and 34.9% of them, respectively, in cardiology outpatients clinics. Physician inertia is one of the major factors in non-adherence to guidelines. These findings highlight that combination therapy is needed in most of the patients.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests: The authors have no conflicts of interest to declare.

Figures

Figure 1.
Figure 1.
Cities of participating centers.
Figure 2.
Figure 2.
Types and doses of statins.
Figure 3.
Figure 3.
The reasons for not using target dose of statin.
See this image and copyright information in PMC

References

    1. Borén J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313 2330. (10.1093/eurheartj/ehz962) - DOI - PMC - PubMed
    1. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion series. J Am Coll Cardiol. 2018;72(10):1141 1156. (10.1016/j.jacc.2018.06.046) - DOI - PubMed
    1. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307(23):2499 2506. (10.1001/jama.2012.6571) - DOI - PMC - PubMed
    1. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459 2472. (10.1093/eurheartj/ehx144) - DOI - PMC - PubMed
    1. Domanski MJ, Tian X, Wu CO,et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76(13):1507 1516. (10.1016/j.jacc.2020.07.059) - DOI - PubMed

Publication types

Substances